AbbVie is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies to treat complex diseases across multiple therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is known for its innovative biologics and pharmaceutical products aimed at addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from chronic and acute health conditions. Through a combination of scientific expertise and strategic partnerships, AbbVie continuously strives to push the boundaries of medical science and expand its portfolio of leading-edge treatments. Read More
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the initiation of its pivotal Phase 2 DAYBreak clinical study. This critical advancement focuses on bexobrutideg (NX-5948), an investigational Bruton's tyrosine kinase (BTK) degrader,
Jason Snipe stays long on AbbVie (ABBV). Guggenheim analyst raises price target. QUALCOMM (QCOM) picked by Jim Lebenthal. Stephanie Link picks Aptiv (APTV). Joe Terranova chooses Palo Alto Networks (PANW).
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
The financial markets were gripped by a sudden wave of apprehension this past week as the Cboe Volatility Index (VIX), often dubbed the "fear gauge," experienced its most significant single-day surge in over six months. On Friday, October 10, 2025, the VIX spiked dramatically, sending a clear signal of heightened
As the closing bell rings on October 10, 2025, the iShares US Dividend Growers Index ETF (CAD-Hedged) (TSX: CUD) stands as a crucial barometer for Canadian income investors seeking exposure to resilient U.S. companies with a consistent history of increasing dividends. While its long-term trajectory showcases robust growth, recent
JPMorgan Chase & Co. (NYSE: JPM) has recently recalibrated its outlook on the biopharmaceutical giant Incyte Corporation (NASDAQ: INCY), with a notable upward revision of its price target for the company's shares. On October 9, 2025, JPMorgan analyst Jessica Fye increased Incyte's price target to $89.00, a significant jump from
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This latest payout marks a significant milestone: the company's 348th consecutive quarterly dividend. The unwavering consistency of
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This payment marks a significant milestone as the company's 348th consecutive quarterly dividend, a testament to its
Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential
On a day where the broader S&P 500 and Nasdaq Composite indices soared to new all-time record highs, the S&P 500 Healthcare sector presented a compelling, albeit nuanced, narrative of market leadership and resilience. While the overall market sentiment exuded robust optimism, the healthcare sector itself showcased a
